Free Trial
NASDAQ:TXG

10x Genomics (TXG) Stock Price, News & Analysis

10x Genomics logo
$12.61 +0.51 (+4.21%)
As of 11:38 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About 10x Genomics Stock (NASDAQ:TXG)

Key Stats

Today's Range
$12.13
$12.66
50-Day Range
$8.10
$13.01
52-Week Range
$6.78
$24.76
Volume
692,089 shs
Average Volume
2.73 million shs
Market Capitalization
$1.55 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.13
Consensus Rating
Hold

Company Overview

10x Genomics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
93rd Percentile Overall Score

TXG MarketRank™: 

10x Genomics scored higher than 93% of companies evaluated by MarketBeat, and ranked 66th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    10x Genomics has received a consensus rating of Hold. The company's average rating score is 2.46, and is based on 7 buy ratings, 5 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    10x Genomics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about 10x Genomics' stock forecast and price target.
  • Earnings Growth

    Earnings for 10x Genomics are expected to grow in the coming year, from ($1.43) to ($1.06) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of 10x Genomics is -9.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of 10x Genomics is -9.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    10x Genomics has a P/B Ratio of 2.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about 10x Genomics' valuation and earnings.
  • Percentage of Shares Shorted

    12.04% of the float of 10x Genomics has been sold short.
  • Short Interest Ratio / Days to Cover

    10x Genomics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in 10x Genomics has recently decreased by 16.17%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    10x Genomics does not currently pay a dividend.

  • Dividend Growth

    10x Genomics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.04% of the float of 10x Genomics has been sold short.
  • Short Interest Ratio / Days to Cover

    10x Genomics has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in 10x Genomics has recently decreased by 16.17%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    10x Genomics has a news sentiment score of 1.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for 10x Genomics this week, compared to 7 articles on an average week.
  • Search Interest

    4 people have searched for TXG on MarketBeat in the last 30 days.
  • MarketBeat Follows

    4 people have added 10x Genomics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, 10x Genomics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $173,238.00 in company stock.

  • Percentage Held by Insiders

    Only 9.39% of the stock of 10x Genomics is held by insiders.

  • Percentage Held by Institutions

    84.68% of the stock of 10x Genomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about 10x Genomics' insider trading history.
Receive TXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter.

TXG Stock News Headlines

10x Genomics: Stuck In Neutral
A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
10x Genomics Settles Patent Dispute With Bruker
See More Headlines

TXG Stock Analysis - Frequently Asked Questions

10x Genomics' stock was trading at $14.36 at the beginning of 2025. Since then, TXG shares have decreased by 15.7% and is now trading at $12.10.

10x Genomics (NASDAQ:TXG) released its quarterly earnings results on Thursday, May, 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.45) by $0.09. 10x Genomics's quarterly revenue was down 2.3% compared to the same quarter last year.
Read the conference call transcript
.

10x Genomics (TXG) raised $297 million in an initial public offering (IPO) on Thursday, September 12th 2019. The company issued 9,000,000 shares at $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Cowen was co-manager.

Top institutional shareholders of 10x Genomics include Pallas Capital Advisors LLC (0.05%), Kera Capital Partners Inc. (0.03%) and Parallel Advisors LLC. Insiders that own company stock include Serge Saxonov, Benjamin J Hindson, John R Stuelpnagel, Adam Taich, Mathai Mammen, Justin J Mcanear, James Wilbur and Alan Mateo.
View institutional ownership trends
.

Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that 10x Genomics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), PayPal (PYPL), Advanced Micro Devices (AMD) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
5/08/2025
Today
7/10/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MEDICAL INFO SYS
Sub-Industry
Measuring And Control Equipment
Current Symbol
NASDAQ:TXG
CIK
1770787
Fax
N/A
Employees
1,240
Year Founded
N/A

Price Target and Rating

High Price Target
$24.00
Low Price Target
$6.50
Potential Upside/Downside
+16.7%
Consensus Rating
Hold
Rating Score (0-4)
2.46
Research Coverage
13 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$182.63 million
Pretax Margin
-24.56%

Debt

Sales & Book Value

Annual Sales
$610.78 million
Price / Cash Flow
N/A
Book Value
$5.81 per share
Price / Book
2.08

Miscellaneous

Free Float
111,572,000
Market Cap
$1.49 billion
Optionable
Optionable
Beta
2.03
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:TXG) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners